Table II.

Newly diagnosed patients with AML (cohort 1): characteristics of responders versus non-responders.

	CR	NR
Total	21 (40.4%)	31 (59.6%)
Overall survival (days)	481	206
Median age, years (range)	74 (45–86)	77 (60–91)
Adverse cytogenetics (n = 18)	6 (33.3%)	12 (66.7%)
WBC > 15 × 103/μL (n = 10)	3 (30%)	7 (70%)
Prior HMA (n = 6)	0	6 (100%)

AML, acute myeloid leukemia; CR, complete response; NR, no response; WBC, white blood cell count; HMA, hypomethylating agent therapy, azacitidine or decitabine.